Literature DB >> 26130413

Promoter hypermethylation of the cysteine protease RECK may cause metastasis of osteosarcoma.

Leisheng Wang1,2, Junbo Ge2, Tian Ma3, Yanpin Zheng1, Shiqiao Lv2, Yu Li2, Shaoxian Liu2.   

Abstract

The present study examined the role of reversion-inducing cysteine-rich protein with Kazal motifs (RECK) promoter hypermethylation as a causative factor in metastasis of osteosarcoma. Using human pathological samples, it is demonstrated that RECK, a cysteine protease that reversibly regulates expression of matrix metalloproteases like matrix metallopeptidase 9 (MMP9), is transcriptionally inhibited in osteosarcoma, especially metastatic variants. This result comes from its promoter hypermethylation, as evaluated in the present study by methylation-specific PCR reaction. The expression of RECK was also significantly diminished in the metastatic variants of osteosarcoma. This downregulation of RECK in advanced grades of osteosarcoma and metastatic grades was also associated with the increased expression of invadosome-specific markers like MMP9, phospho-FAK, and integrins, suggesting the complex contributions of RECK in the prevention of metastasis and its downregulation as a causative factor in osteosarcoma metastasis.

Entities:  

Keywords:  Bone tumors; Metastasis; Osteosarcoma; Promoter hypermethylation; RECK

Mesh:

Substances:

Year:  2015        PMID: 26130413     DOI: 10.1007/s13277-015-3688-4

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  15 in total

1.  Expression of matrix metalloproteinase regulator, RECK, and its clinical significance in osteosarcoma.

Authors:  Jianda Xu; Sujia Wu; Xin Shi
Journal:  J Orthop Res       Date:  2010-12       Impact factor: 3.494

Review 2.  Significance of MTA1 in the molecular characterization of osteosarcoma.

Authors:  Sung Sun Kim; Yong-Koo Park
Journal:  Cancer Metastasis Rev       Date:  2014-12       Impact factor: 9.264

Review 3.  Type beta transforming growth factor regulates expression of genes encoding bone matrix proteins.

Authors:  M Noda; G A Rodan
Journal:  Connect Tissue Res       Date:  1989       Impact factor: 3.417

4.  MMP9 mediates MICA shedding in human osteosarcomas.

Authors:  Dahui Sun; Xu Wang; Haixia Zhang; Lijuan Deng; Yan Zhang
Journal:  Cell Biol Int       Date:  2011-06       Impact factor: 3.612

5.  RECK expression in osteosarcoma: correlation with matrix metalloproteinases activation and tumor invasiveness.

Authors:  Hyun-Guy Kang; Han-Soo Kim; Kap-Jung Kim; Joo Han Oh; Mi-Ra Lee; So Mi Seol; Ilkyu Han
Journal:  J Orthop Res       Date:  2007-05       Impact factor: 3.494

Review 6.  A systematic review of matrix metalloproteinase 9 as a biomarker of survival in patients with osteosarcoma.

Authors:  Hui Li; Kun Zhang; Li-hong Liu; Yurong Ouyang; Jie Bu; Hong-bin Guo; Tao Xiao
Journal:  Tumour Biol       Date:  2014-02-28

Review 7.  New molecular insights into osteosarcoma targeted therapy.

Authors:  Jilong Yang; Wei Zhang
Journal:  Curr Opin Oncol       Date:  2013-07       Impact factor: 3.645

Review 8.  EMT transcription factors: implication in osteosarcoma.

Authors:  Guoqiong Yang; Jian Yuan; Kanghua Li
Journal:  Med Oncol       Date:  2013-08-24       Impact factor: 3.064

9.  Correlation between the expression of vegf and survival in osteosarcoma.

Authors:  André Mathias Baptista; André Ferrari De França Camargo; Renée Zon Filippi; Cláudia Regina Gomes Cardim Mendes De Oliveira; Raymundo Soares De Azevedo Neto; Olavo Pires De Camargo
Journal:  Acta Ortop Bras       Date:  2014       Impact factor: 0.513

10.  Downregulation of ERK signaling impairs U2OS osteosarcoma cell migration in collagen matrix by suppressing MMP9 production.

Authors:  Barun Poudel; DO-Kuk Kim; Hyeon-Hui Ki; Young-Bae Kwon; Young-Mi Lee; Dae-Ki Kim
Journal:  Oncol Lett       Date:  2013-11-04       Impact factor: 2.967

View more
  6 in total

1.  An integrative analysis of DNA methylation in osteosarcoma.

Authors:  Jie Xu; Deng Li; Zhiqing Cai; Yingbin Zhang; Yulin Huang; Baohua Su; Ruofan Ma
Journal:  J Bone Oncol       Date:  2017-05-19       Impact factor: 4.072

Review 2.  Epigenetic inactivation of tumour suppressor coding and non-coding genes in human cancer: an update.

Authors:  Pere Llinàs-Arias; Manel Esteller
Journal:  Open Biol       Date:  2017-09       Impact factor: 6.411

3.  Epigenetically silenced PTPRO functions as a prognostic marker and tumor suppressor in human lung squamous cell carcinoma.

Authors:  Fei Ming; Qianqiang Sun
Journal:  Mol Med Rep       Date:  2017-05-31       Impact factor: 2.952

4.  GAS5 Regulates RECK Expression and Inhibits Invasion Potential of HCC Cells by Sponging miR-135b.

Authors:  Liang Yang; Jianshuai Jiang
Journal:  Biomed Res Int       Date:  2019-01-13       Impact factor: 3.411

5.  miR-590-5p regulates gastric cancer cell growth and chemosensitivity through RECK and the AKT/ERK pathway.

Authors:  Bo Shen; Shaorong Yu; Yan Zhang; Yuan Yuan; Xiaoyou Li; Jian Zhong; Jifeng Feng
Journal:  Onco Targets Ther       Date:  2016-10-03       Impact factor: 4.147

Review 6.  Multifaceted Roles of DNA Methylation in Neoplastic Transformation, from Tumor Suppressors to EMT and Metastasis.

Authors:  Laura Casalino; Pasquale Verde
Journal:  Genes (Basel)       Date:  2020-08-12       Impact factor: 4.096

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.